These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241 [TBL] [Abstract][Full Text] [Related]
10. Sox9, Hopx, and survivin and tuft cell marker DCLK1 expression in normal canine intestine and in intestinal adenoma and adenocarcinoma. Reineking W; Schauerte IE; Junginger J; Hewicker-Trautwein M Vet Pathol; 2022 May; 59(3):415-426. PubMed ID: 35220825 [TBL] [Abstract][Full Text] [Related]
11. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner. Razi S; Sadeghi A; Asadi-Lari Z; Tam KJ; Kalantari E; Madjd Z Clin Exp Med; 2021 Feb; 21(1):139-147. PubMed ID: 32965580 [TBL] [Abstract][Full Text] [Related]
12. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer. Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-195 regulates Tuft cell function in the intestinal epithelium by altering translation of DCLK1. Kwon MS; Chung HK; Xiao L; Yu TX; Wang SR; Piao JJ; Rao JN; Gorospe M; Wang JY Am J Physiol Cell Physiol; 2021 Jun; 320(6):C1042-C1054. PubMed ID: 33788631 [TBL] [Abstract][Full Text] [Related]
15. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1. Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411 [TBL] [Abstract][Full Text] [Related]
17. Brg1 is required to maintain colorectal cancer stem cells. Yoshikawa T; Fukuda A; Omatsu M; Namikawa M; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Ogawa S; Masuo K; Goto N; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Kawada K; Takaishi S; Seno H J Pathol; 2021 Nov; 255(3):257-269. PubMed ID: 34415580 [TBL] [Abstract][Full Text] [Related]
18. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277 [TBL] [Abstract][Full Text] [Related]
20. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer. Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]